Disclosed herein are nerve xenografts and methods of using such for repairing and/or protecting a nerve tissue in a human patient. The subject matter disclosed herein generally relates to nerve xenografts derived from genetically engineered source animals, and use of such nerve xenografts for repairing and/protecting nerve tissue in a human patient, e.g., for reconstruction of large peripheral nerve gaps, treatment of spinal cord injuries and ailments, and other therapies.

Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.

Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.

Porous implantable devices for housing one or more therapeutic agents are disclosed herein. The implantable devices include a porous outer wall defining an interia or void. The interior void houses a carrier material carrying a first therapeutic agent. The implantable devices are made by patterning at least a portion of a polymerizable substrate into a polymerized three-dimensional porous outer wall surrounding an interior void. This can be achieved by two-photon polymerization techniques. A first therapeutic agent is then added to the interior void, which is then sealed. Methods of treating diseases using the implantable devices are disclosed herein. The methods include implanting the implantable device at a target area and locally releasing a therapeutically effective dosage of a first therapeutic agent from the interior void. The implantable devices can also be used in methods of screening potentially therapeutic agents for desired biological responses.

Porous implantable devices for housing one or more therapeutic agents are disclosed herein. The implantable devices include a porous outer wall defining an interia or void. The interior void houses a carrier material carrying a first therapeutic agent. The implantable devices are made by patterning at least a portion of a polymerizable substrate into a polymerized three-dimensional porous outer wall surrounding an interior void. This can be achieved by two-photon polymerization techniques. A first therapeutic agent is then added to the interior void, which is then sealed. Methods of treating diseases using the implantable devices are disclosed herein. The methods include implanting the implantable device at a target area and locally releasing a therapeutically effective dosage of a first therapeutic agent from the interior void. The implantable devices can also be used in methods of screening potentially therapeutic agents for desired biological responses.

Provided are compositions and methods for treatment of cancer and for adoptive T cell therapy (ACT). The compositions comprise one or more derivatives of tricin 7-O-β-D-glucopyranoside (ANTARTINA®). The compositions comprise one or more pharmaceutically acceptable excipients convenient for delivery of the tricin 7-O-β-D-glucopyranoside derivatives. Tricin 7-O-β-D-glucopyranoside derivatives described herein include acetylated tricin 7-O-β-D-glucopyranoside, as well as glucose, maltose, cellobiose, lactose, xylose, and galactose derivatives. The methods include treatment, or reduction in the risk of suffering from, colorectal cancer and hepatocellular cancer.

Provided are compositions and methods for treatment of cancer and for adoptive T cell therapy (ACT). The compositions comprise one or more derivatives of tricin 7-O-β-D-glucopyranoside (ANTARTINA®). The compositions comprise one or more pharmaceutically acceptable excipients convenient for delivery of the tricin 7-O-β-D-glucopyranoside derivatives. Tricin 7-O-β-D-glucopyranoside derivatives described herein include acetylated tricin 7-O-β-D-glucopyranoside, as well as glucose, maltose, cellobiose, lactose, xylose, and galactose derivatives. The methods include treatment, or reduction in the risk of suffering from, colorectal cancer and hepatocellular cancer.

In various aspects and embodiments, the present invention provides methods for maintaining motor neuron health in the spinal cord and pro-regenerative capacity of a proximal nerve segment subsequent to a nerve injury in a subject in need thereof, the methods comprising transplanting a stretch-grown tissue engineered nerve graft (TENG) into a proximal site contacting the proximal nerve segment.

The present invention relates to a composition for treating a spinal cord injury and provides a composition for treating a spinal cord injury comprising, as an active ingredient, stem cells treated with a particular compound and then cultured.

The present invention relates to a composition for treating a spinal cord injury and provides a composition for treating a spinal cord injury comprising, as an active ingredient, stem cells treated with a particular compound and then cultured.